Sanofi Increases its Investment in Oncology in Spain by 35% to 6.7M in 2021

Sanofi reaffirms its commitment to oncology. The French pharmaceutical company invested last year in Spain $7.1 million (€6.7 million) in oncology research, about 35% more compared to 2020, the multinational reports in a statement.

In total, in 2021, the company invested $53.4 million (€50 million) in Spain, in research and development (R&D) of innovative therapeutic solutions. Sanofi currently has ten molecules in different phases of research for different indications, with a special focus on those types of cancer that are difficult to treat. Specifically in Spain, of the 71 clinical studies that the company launched last year, 25 are in the oncology area.

Sanofi’s aim is to create the next generation of cancer drugs, addressing critical gaps and unmet needs of the medical community and patients. To this end, it is investing in new technology platforms to transform scientific discoveries into new approaches and potential treatments.

Another of the company’s priorities is to expand access to therapies and provide resources and support tools to patients, always joining forces and collaborating with all health agents involved in the approach to oncological diseases.

Born2Invest mobile application is bringing all the biotech and business news from trusted sources to a single screen so you can stay on top of the market. The application is aggregating the most important and breaking news from relevant websites, the list is always revised and updated with new resources. Read more about Sanofi’s plans in Spain with the Born2Invest mobile app, available for free for both Android and iOS devices.

Sanofi last year added 25 clinical studies in oncology in Spain

“Oncology is one of Sanofi’s bets for the future; we focus on the discovery and development of treatments based on solid scientific criteria and innovative technologies to respond to the unmet needs of oncology patients,” explained Raquel Tapia, general manager of Sanofi Iberia’s specialized medicine unit. “In this sense, we are proud to announce that the Spanish medical community and patients now have new therapeutic options for lung cancer and multiple myeloma,” she added.

Immuno-oncology and molecular oncology are two of Sanofi’s most promising bets to tackle some of the most difficult-to-treat cancers. While immuno-oncology research is focused on finding new ways to boost the immune system so that it is able to detect and attack tumors, the focus of molecular oncology is on precision medicine, to identify a tumor’s genetic mutations so that researchers can tailor their treatment.

In terms of oncology research lines, Sanofi’s strategy focuses on the following diseases: multiple myeloma and other blood cancers, skin cancer, lung cancer, breast cancer, and other hormonal cancers.

In recent weeks, two new oncology treatments developed by Sanofi have become available in Spain to treat some of the most difficult cancers to treat: lung cancer and multiple myeloma.

__

(Featured image by Ousa Chea via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.